Is the RSV Vaccine a Live Vaccine? A Look at Current Options

None of the RSV vaccines currently approved for use in the United States or Europe contain live virus. The two licensed products, Arexvy (GSK) and Abrysvo (Pfizer), are protein subunit vaccines built around a lab-made piece of the virus rather than any form of the actual pathogen. A third candidate from Moderna uses mRNA technology, similar in concept to some COVID-19 vaccines. The question comes up often because many familiar vaccines, such as those for measles or chickenpox, do use weakened live virus, and people reasonably want to know whether the RSV shot works the same way. It does not, and the reasons for that choice trace back to a tragic episode in vaccine history that reshaped the entire field.

What the Approved RSV Vaccines Actually Contain

Both Arexvy and Abrysvo work by presenting your immune system with a single protein from RSV’s surface, known as the fusion (F) protein. This protein is what the virus uses to break into your cells, and antibodies that block it can prevent infection. Neither vaccine contains whole virus, live or dead. They contain only the F protein, manufactured in a lab using recombinant DNA technology, meaning no RSV is grown and harvested to make them.

The two vaccines differ in some design details. Abrysvo is bivalent, containing stabilized prefusion F protein antigens from both of the major RSV subgroups, RSV-A and RSV-B.¹ Arexvy targets the same F protein but includes an adjuvant system called AS01, which contains two immune-stimulating compounds that work together to amplify the body’s response to the vaccine.² Think of it as the difference between showing someone a photograph and showing them the same photograph under a spotlight: the adjuvant makes the immune system pay more attention to what it’s seeing. Abrysvo does not include an adjuvant.

This protein subunit approach is fundamentally different from a live vaccine. A live-attenuated vaccine uses a weakened but replicating version of the pathogen, which mimics a mild infection to train the immune system. A subunit vaccine skips that step entirely. There is no replication, no infection, and no possibility of giving you the disease. The vaccine delivers a single piece of the virus in a form that cannot reproduce.

Why a Live RSV Vaccine Was Never Brought to Market

The history here matters because it explains not just the design of today’s vaccines but also why it took over sixty years after RSV was first identified to get any vaccine approved at all. In the 1960s, researchers tested a formalin-inactivated RSV vaccine (essentially, killed whole virus) in infants. The results were catastrophic. Among 31 infants who received the vaccine, 20 later became infected with RSV, and 16 of those 20 were hospitalized with unusually severe disease. Two infants died.³ Rather than protecting them, the vaccine had primed their immune systems to overreact dangerously when they encountered the real virus.

Later research showed that the inactivated vaccine produced antibodies that could bind to RSV but couldn’t effectively neutralize it, leading to immune complex deposition and intense inflammation. The immune response was skewed toward a type of inflammation driven by specific subsets of helper T cells: one subset caused airway hyperreactivity and mucus overproduction, while another drove airway obstruction and weight loss.⁴ The problem appeared to lie in how the virus was presented to the immune system rather than which specific viral proteins were included. Studies in mice showed that even when key proteins were deleted from the inactivated vaccine, the enhanced disease still occurred, suggesting the method of preparation itself was driving the harmful immune response.⁵

This disaster effectively froze RSV vaccine development for decades. Researchers knew they had to avoid triggering that same harmful immune profile, which meant any future vaccine needed to generate antibodies that actually neutralized the virus rather than just binding to it uselessly.

The Prefusion F Protein Breakthrough

The key that eventually unlocked RSV vaccine development was a structural insight about the F protein itself. RSV’s fusion protein exists in two shapes: a “prefusion” form before it attaches to a cell and a “postfusion” form after. The most potent neutralizing antibodies target a site that only exists on the prefusion version. The formalin-inactivated vaccine from the 1960s inadvertently presented the postfusion form, which triggered binding antibodies with weak neutralizing activity.

Researchers used the atomic structure of the prefusion F protein to engineer stabilized versions that held their shape even under harsh conditions like extreme temperatures and pH changes.⁶ This was the foundation for both Arexvy and Abrysvo. By locking the F protein in its prefusion conformation, the vaccines ensure the immune system sees the right target and produces the kind of antibodies that can actually block infection. It took years to figure out how to stabilize that shape for manufacturing, but once that problem was solved, the path to approval opened up relatively quickly.

RSV Vaccination During Pregnancy

One of the more distinctive uses of RSV vaccines involves vaccinating pregnant people to protect their newborns. Abrysvo is approved for this purpose, given between 32 and 36 weeks of pregnancy during RSV season. The idea is that the mother’s immune system produces antibodies in response to the vaccine, and those antibodies cross the placenta to the baby before birth.

This strategy has shown strong results in early infancy. In clinical trial data, maternal RSV vaccination demonstrated high protection against severe RSV lower respiratory tract illness in infants, with efficacy reaching roughly 80% in the first 90 days of life.⁷ The timing of vaccination matters: getting the shot earlier in the approved window, at least five weeks before delivery, results in more efficient transfer of antibodies across the placenta.⁸ Preterm infants, however, tend to receive fewer antibodies through this route compared with full-term babies.⁹

This is not the only way to protect infants. An alternative is giving babies a monoclonal antibody (nirsevimab or clesrovimab) directly after birth. Each approach has trade-offs. Maternal vaccination provides protection from the moment of birth, avoids an injection for the infant, and may offer some benefit to the mother as well. But it requires a narrow gestational window and seasonal timing, and the naturally transferred antibodies wane faster than engineered monoclonal antibodies do. Monoclonal antibodies deliver a reliable, high dose of neutralizing antibody and can be timed for peak RSV exposure, but they are expensive, have faced supply shortages, and carry a small risk of allergic reactions.¹⁰ The current recommendation from the American Academy of Pediatrics is that infants should receive one or the other, though clinical trials are exploring whether combining both adds benefit.

Live-Attenuated RSV Vaccines in Development

Live-attenuated RSV vaccines do exist, but only in clinical research. They have never been approved for general use. These candidates are being developed primarily for infants and young children, a population where the subunit vaccines approved for adults cannot be used directly. Live-attenuated RSV vaccines have some theoretical advantages for this age group: they are given as nose drops rather than injections, they stimulate immune responses both in the bloodstream and locally in the airways, and importantly, they have not been linked to the enhanced disease that doomed the inactivated vaccine in the 1960s.¹¹

Another practical advantage is that live-attenuated vaccines can replicate in young infants even when those infants still carry maternal antibodies. Many other vaccine types get blunted by preexisting antibodies, which is one reason infant RSV vaccination has been so challenging. Development of these candidates involves either traditional methods like serial passage in cold conditions or modern reverse genetics to introduce specific weakening mutations. None have yet advanced through the regulatory process to approval, but several are in clinical trials. So if you’re asking whether an RSV vaccine you or your family member received is live, the answer for now is no.

How Well the Vaccines Work and How Long Protection Lasts

Real-world data on the currently approved vaccines in adults aged 60 and older show strong protection. A large study found that vaccine effectiveness against RSV-related illness requiring medical attention was about 70%, and effectiveness against RSV hospitalization ranged from roughly 65% to 72% depending on age group.¹² Protection was somewhat higher in adults 75 and older than in those between 60 and 74, which likely reflects the higher baseline risk in older individuals making the vaccine’s benefit more measurable.

The durability question is trickier. In a clinical trial tracking Abrysvo across two RSV seasons, effectiveness against RSV-related hospitalization was about 83% in the first season but dropped to roughly 56% in the second, though that second-season estimate had wide confidence intervals. Over both seasons combined, effectiveness settled around 71%.¹³ This waning is not unusual for protein subunit vaccines and has implications for whether people will eventually need repeat doses. The evidence on whether or when to revaccinate is still developing.

For context on why RSV immunity is so hard to sustain, research in animal models has shown that even natural RSV infection produces disappointingly weak long-term immune memory, particularly in the airways. One study found that mice infected with RSV developed significantly lower levels of local antibody-producing memory cells compared with mice given a well-designed subunit vaccine, which may help explain why people can get reinfected with RSV throughout their lives.¹⁴ The virus itself appears to do a poor job of teaching the immune system to remember it, which is a fundamental challenge for any vaccine strategy.

The Guillain-Barré Signal and Other Safety Considerations

The most closely watched safety issue with the approved RSV vaccines is a possible link to Guillain-Barré syndrome (GBS), a rare neurological condition where the immune system attacks the nerves. This risk was flagged during clinical trials and has continued to be monitored after approval. CDC surveillance in the first year found rates of GBS reports slightly above expected background levels for both vaccines.¹⁵

A larger study of Medicare beneficiaries found a statistically significant increased incidence of GBS following Arexvy (the adjuvanted vaccine), with an attributable risk of roughly 6 to 7 extra cases per million doses. For Abrysvo, there was also a numerically elevated risk of about 9 extra cases per million doses, though the finding did not reach statistical significance.¹⁶ To put those numbers in perspective, we are talking about single-digit extra cases per million vaccinated people, and GBS occurs at a background rate in the general population even without vaccination. Monitoring continues, and for most people the benefit of preventing severe RSV disease substantially outweighs this rare risk, but it is something your doctor should discuss with you, especially if you have a history of GBS.

Otherwise, the common side effects are what you’d expect from any vaccine: injection site pain, fatigue, headache, and muscle aches. The safety profile for maternal use of Abrysvo is being watched especially closely for any signal related to preterm birth, though trial data have been generally reassuring.⁷

Getting the RSV Vaccine Alongside Flu or COVID Shots

A practical concern for many people, especially older adults heading into fall, is whether you can get the RSV vaccine at the same visit as a flu shot or COVID booster. The evidence here is reassuring. Studies of Moderna’s mRNA RSV candidate given alongside seasonal flu vaccine or a COVID-19 booster found that immune responses were not meaningfully diminished for any of the vaccines when given together compared with separate visits.¹⁷

In a detailed phase 3 trial, co-administration of the mRNA RSV vaccine with a seasonal flu shot did produce slightly lower RSV antibody levels compared with giving the RSV vaccine alone, but the responses still met pre-specified thresholds. Flu antibody responses were essentially unaffected. When the RSV vaccine was given alongside a COVID-19 booster, the pattern was similar: a modest dip in RSV-specific antibodies but no meaningful impact on COVID antibodies.¹⁸ The practical takeaway is that you do not need to schedule separate visits for your RSV vaccine, which removes a real barrier for people who might otherwise skip it.

Who the Vaccines Are Approved For and Who Is Still Waiting

Right now, approved RSV vaccines are available for two groups: adults aged 60 and older (both Arexvy and Abrysvo) and pregnant individuals between 32 and 36 weeks of gestation (Abrysvo only). The mRNA candidate from Moderna is under regulatory review and could expand the options if approved. The pipeline also includes recombinant vector-based candidates and the live-attenuated intranasal candidates mentioned earlier.¹⁹

The population still most underserved is young children, particularly those in their first and second RSV seasons. Infants under six months can be protected through maternal vaccination or monoclonal antibodies, but there is no approved vaccine that you give directly to a baby or toddler. That is precisely the gap that live-attenuated candidates aim to fill, since the subunit vaccines are not designed for naive infant immune systems and carry at least theoretical concerns about the enhanced disease pattern from the 1960s. Until a pediatric vaccine clears clinical trials, the protection strategy for young children remains indirect: either passively through antibodies from vaccinated mothers or artificially through injected monoclonal antibodies.

Cost and Access Realities

RSV vaccines are not cheap, and cost-effectiveness analyses have produced mixed results depending on the age group. For adults 65 and older in the US, vaccination falls within ranges that health economists generally consider reasonable, though not a bargain. For adults between 60 and 64, the cost per quality-adjusted life-year saved is roughly double what it is for older groups, because younger adults get severely ill from RSV less often.²⁰ The biggest drivers of whether vaccination makes economic sense are vaccine price, how common severe RSV hospitalizations are in a given age group, and how long the protection lasts. If effectiveness persists well beyond two seasons without needing a booster, the math improves considerably. Similar analyses in Japan found that vaccination of adults 60 and older prevented a large number of cases and deaths and was considered cost-effective under their thresholds.²¹

Insurance coverage varies. In the US, most private insurers and Medicare Part D have been covering the vaccines, though out-of-pocket costs may apply depending on your plan. For many older adults, the practical question is less “is this vaccine worth it” and more “can I get it without a significant copay,” which depends entirely on individual insurance details.